Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients

The aim of this study was to identify baseline prognostic factors for poor clinical outcome of HIV-associated cryptococcal meningitis. We conducted a trial in Thailand and the USA comparing low- and high-dose concomitant use of amphotericin B and fluconazole for HIV-associated cryptococcal meningitis to amphotericin B followed by fluconazole. Subjects who were either alive and cerebrospinal fluid (CSF) culture-positive or dead were considered to have a poor outcome. At day 14, baseline characteristics associated with poor outcome included: low weight, high CSF cryptococcal antigen (CrAg) titre and low CSF white blood cell (WBC) count. At day 70, the associated baseline characteristics included: CSF CrAg titre >1:1024 and low Karnofsky performance status. Overall, consistent with published findings, low weight, high CSF CrAg titre and low CSF WBC counts at baseline were predictors for poor clinical outcome. In addition, we found that low Karnofsky performance status was predictive of poor outcome. Prompt management with appropriate antifungal therapy for this particular group of patients may improve the outcomes.

[1]  S. Jaffar,et al.  Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J. Sobel,et al.  A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  John T Brooks,et al.  Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. , 2009, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[4]  D. Sloan,et al.  Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings. , 2008, The Cochrane database of systematic reviews.

[5]  D. Boulware,et al.  Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Kaewkungwal,et al.  Survival time of HIV-infected patients with cryptococcal meningitis. , 2007, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[7]  M. Alvarez,et al.  Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy , 2006, AIDS.

[8]  K. Wannemuehler,et al.  Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence , 2006, AIDS.

[9]  N. White,et al.  Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial , 2004, The Lancet.

[10]  E. Graviss,et al.  The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  A. Simpson,et al.  A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. , 2001, The Journal of infection.

[12]  R. Heyderman,et al.  Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M. Saag,et al.  Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. , 1997, The New England journal of medicine.

[14]  J. McCutchan,et al.  Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Saag,et al.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. , 1992, The New England journal of medicine.

[16]  L. Chan,et al.  Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. , 1990, Annals of internal medicine.

[17]  S. Chuck,et al.  Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. , 1989, The New England journal of medicine.

[18]  D. Alling,et al.  A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. , 1979, The New England journal of medicine.

[19]  J. Bennett,et al.  Prognostic factors in cryptococcal meningitis. A study in 111 cases. , 1974, Annals of internal medicine.

[20]  M. Saag,et al.  Diagnosis and Management of Increased Intracranial Pressure in Patients with AIDS and Cryptococcal Meningitis , 2000 .

[21]  R. Larsen,et al.  Early mycological treatment failure in AIDS-associated cryptococcal meningitis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.